Safeplus International Holdings Ltd. (ACAI)

[Jagman]

Return of the fluffies, pps support attempt has returned!!!

Biophan Posts Presentation Outlining Progress in Growth of Company's Biophan Europe Division
Tuesday August 2, 3:30 am ET
Online Presentation Describes Technologies and Application Development for Advances in MRI Visualization of Medical Devices


ROCHESTER, N.Y.--(BUSINESS WIRE)--Aug. 2, 2005--Biophan Technologies, Inc. (OTCBB: BIPH - News), a developer of next-generation biomedical technology, has announced the online availability of an electronic presentation that provides a detailed overview of the Company's Biophan Europe division, including a review of their key research and product development initiatives. Biophan Europe, based in Germany, is developing breakthrough solutions that make lifesaving implantable medical devices, such as vascular stents, clearly imageable under Magnetic Resonance Imaging (MRI).

The presentation was part of an address given by Biophan Europe President and CEO, Dr. Michael Friebe, at Biophan's recent annual shareholders meeting in Rochester, New York. It also describes the extensive European network of world-class MRI research centers that help maintain Biophan Europe's cutting-edge position.

Earlier this year, Biophan acquired AMRIS GmbH, a company based in Castrop-Raxel, Germany, that was developing advanced solutions in MRI visualization that complemented Biophan's own technologies. Following the acquisition, AMRIS was renamed Biophan Europe. The establishment of Biophan Europe gave Biophan access to a large network of leading MRI partner research centers, including the University of Aachen. It also brought access to extremely valuable testing facilities at the AMRIS subsidiary, MR:comp GmbH (www.mrcomp.com), one of the few independent and most advanced MRI test laboratories in the world.

"Acquiring AMRIS as our Biophan Europe division has been one of our Company's most significant moves," said Biophan CEO, Michael Weiner. "We have been strengthened by the addition of the key AMRIS personnel to our ranks, as well as by the unique access to the European research community, where some of the most exciting research into MRI is being conducted. One of the many advanced areas where Biophan Europe is a leader is the emerging field of interventional MRI, which uses the safer imaging modality of MRI to conduct a new class of advanced, minimally invasive surgical procedures."

Mr. Weiner added: "As this online presentation describes, Biophan Europe is positioned to help us accelerate our development and introduction of new products into the marketplace."

In addition to Dr. Friebe, Biophan Europe's key scientific collaborators include Dr. Andreas Melzer, a recognized world authority on MRI visualization technology, and Gregor Schaefers, CEO of MR:comp.

MRI visualization technologies developed at Biophan Europe include "active" as well as "passive" solutions that enable MRI visualization of stents, catheters, filters, and other new applications.

Dr. Friebe's presentation, and others delivered at the meeting can be viewed online at http://www.biophan.com/presentations.php.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 142 U.S. patents, licenses, or applications. This total includes 38 issued U.S. patents, 9 recently-allowed applications that will issue as patents in the near future, and 95 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.



--------------------------------------------------------------------------------
Contact:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037